RxDoctor Payments Data

Matthew Schindler, MD

Neurology · Waterbury, CTNPI 1184949414

Payments from drug & device makers

$11,397in general payments, 2019–2025

Across 53 payments — averaging $215.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$6K
  • EMD Serono, Inc.$2K
  • TG Therapeutics, Inc.$1K
  • Biogen$940
  • Bristol Myers Squibb$924
  • Novartis$196
  • plus $122 from 1 others

What the payments were for

  • Consulting fees$3,57531%
  • Speaking & faculty fees$3,46130%
  • Travel & lodging$6816%
  • Food & beverage$3,67632%
  • Education$40%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi7$6,033
EMD Serono, Inc.23$2,001
TG Therapeutics, Inc.5$1,180
Biogen8$940
Bristol Myers Squibb5$924
Novartis4$196
AstraZeneca1$122

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,397 in reported general payments places this provider in the 65th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$13,218
Medicare patients
84
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab86$790,662
CopaxoneGlatiramer Acetate32$235,102
AubagioTeriflunomide12$110,351
Avonex Pen (4 Pack)Interferon Beta-1a12$97,599
Dimethyl Fumarate22$90,389
AmpyraDalfampridine12$50,262
Glatiramer Acetate13$27,124
Dalfampridine ErDalfampridine93$26,755
Teriflunomide17$13,898
Baclofen80$1,713
Lidocaine12$1,568
AmantadineAmantadine Hcl21$1,057
Modafinil18$862
Gabapentin29$659
Tizanidine Hcl26$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$6,033$110,35112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 280 neurology providers in Connecticut.

Other neurology in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →